CervoMed Inc. (CRVO), a clinical-stage biopharmaceutical company, on Wednesday announced that investigators will present results from the Phase 2b RewinD-LB study demonstrating that neflamapimod slows clinical progression in Dementia with Lewy Bodies or DLB at the AD/PD 2025 conference on April 5, 2025.
The study's 16-week Extension phase showed that neflamapimod led to improvements in cognitive and motor function, with a clinically meaningful reduction in disease progression compared to controls, as measured by CDR-SB (Clinical Dementia Rating Sum of Boxes) and CGIC (Clinical Global Impression of Change).
Patients receiving the New Capsules, which achieved target plasma drug levels, experienced:
-- Slower clinical decline compared to those on the Old Capsules and placebo.
-- A 40 percent lower incidence of worsening symptoms.
-- Significantly fewer falls (4 percent vs. 15.2 percent with Old Capsules and 19.7 percent with placebo).
Both the New and Old Capsules were well-tolerated, with no new safety concerns identified.
CervoMed plans to complete the full 32-week Extension phase in 2025 and engage with regulatory authorities to finalize plans for a Phase 3 trial.
These findings provide proof-of-concept for neflamapimod as a potential disease-modifying therapy for DLB, a condition with no currently approved treatments that slow disease progression.
Currently, CRVO is trading at $13.07 up by 31.76 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.